Age-Dependence and Aging-Dependence: Neuronal Loss and Lifespan in a C. elegans Model of Parkinson's Disease.

Apfeld J, Fontana W.

Biology (Basel). 2017 Dec 23;7(1). pii: E1. doi: 10.3390/biology7010001.

A MDS-UPDRS Part II (motor experiences of daily living) score to predict recurrent falls in people with Parkinson's disease.

Almeida LRS, Valenca GT, Oliveira-Filho J.

J Neurol Sci. 2017 Dec 15;383:114-115. doi: 10.1016/j.jns.2017.10.047. Epub 2017 Oct 28. No abstract available.

Comment: β-Amyloid pathology and Parkinson disease.

Dodel R.

Neurology. 2017 Dec 5;89(23):2339. doi: 10.1212/WNL.0000000000004756. Epub 2017 Nov 8. No abstract available.

Neurotrophin Expression in Lymphocytes: a Powerful Indicator of Degeneration in Parkinson's Disease, Amyotrophic Lateral Sclerosis and Ataxia.

Sadanand A, Janardhanan A, Vanisree AJ, Pavai T.

J Mol Neurosci. 2017 Dec 16. doi: 10.1007/s12031-017-1014-x. [Epub ahead of print]

The non-motor symptoms of Parkinson's disease of different motor types in early stage.

Zhong LL, Song YQ, Cao H, Ju KJ, Yu L.

Eur Rev Med Pharmacol Sci. 2017 Dec;21(24):5745-5750. doi: 10.26355/eurrev_201712_14021.

Dystonia as an unusual presentation of systemic mastocytosis: possible link between histamine release and movement disorders.

Phillips A, Hoyte FCL, Leung DYM.

J Allergy Clin Immunol Pract. 2017 Jul 27. pii: S2213-2198(17)30430-0. doi: 10.1016/j.jaip.2017.06.005. [Epub ahead of print] No abstract available.

Mechanistic evaluation of neuroprotective effect of estradiol on rotenone and 6-OHDA induced Parkinson's disease.

Shen D, Tian X, Zhang B, Song R.

Pharmacol Rep. 2017 Dec;69(6):1178-1185. doi: 10.1016/j.pharep.2017.06.008. Epub 2017 Jul 8.

The serotonergic system in Parkinson's patients with dyskinesia: evidence from imaging studies.

Pagano G, Niccolini F, Politis M.

J Neural Transm (Vienna). 2017 Dec 20. doi: 10.1007/s00702-017-1823-7. [Epub ahead of print] Review.

MicroRNA-30e regulates neuroinflammation in MPTP model of Parkinson's disease by targeting Nlrp3.

Li D, Yang H, Ma J, Luo S, Chen S, Gu Q.

Hum Cell. 2017 Dec 22. doi: 10.1007/s13577-017-0187-5. [Epub ahead of print]

Conscious attention defect and inhibitory control deficit in Parkinson's Disease-Mild Cognitive Impairment: A comparison study with Amnestic Mild Cognitive Impairment multiple domain.

Cammisuli DM, Sportiello MT.

Psychiatr Danub. 2017 Dec;29(4):437-445. doi: 10.24869/psyd.2017.437.

Cognitive dysfunction and symptoms of movement disorders in adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.

Ikeuchi T, Mezaki N, Miura T.

Parkinsonism Relat Disord. 2017 Aug 16. pii: S1353-8020(17)30299-7. doi: 10.1016/j.parkreldis.2017.08.018. [Epub ahead of print]

Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features.

Goldman JG, Andrews H, Amara A, Naito A, Alcalay RN, Shaw LM, Taylor P, Xie T, Tuite P, Henchcliffe C, Hogarth P, Frank S, Saint-Hilaire MH, Frasier M, Arnedo V, Reimer AN, Sutherland M, Swanson-Fisch

Mov Disord. 2017 Dec 4. doi: 10.1002/mds.27232. [Epub ahead of print]

Total Hip Arthroplasty in Patients With Parkinson Disease: Improved Outcomes With Dual Mobility Implants and Cementless Fixation.

Lazennec JY, Kim Y, Pour AE.

J Arthroplasty. 2017 Dec 5. pii: S0883-5403(17)31067-7. doi: 10.1016/j.arth.2017.11.062. [Epub ahead of print]

Principles and approaches to the treatment of immune-mediated movement disorders.

Mohammad SS, Dale RC.

Eur J Paediatr Neurol. 2017 Dec 19. pii: S1090-3798(17)31734-8. doi: 10.1016/j.ejpn.2017.11.010. [Epub ahead of print] Review.

[Movement disorders units and management of motor fluctuations in advanced Parkinson's disease].

de Fabregues O, Gironell A, Rossello-Jimenez D, Regueras E.

Rev Neurol. 2017 Nov 1;65(9):396-404. Spanish.